Pramodini Medicare IPO

Past issues are context, not a forecast — this issue is a different company at a different price. We show it because "how have issues like this one actually opened" is a question with a real answer, and grey-market premium is not that answer.

Pramodini Medicare is a diagnostic service provider in India, offering technology-enabled diagnostic services to public and private hospitals, government PSUs and medical colleges across tier I, tier II and tier III cities. Its services are divided into three categories: radiology, clinical laboratory and nuclear medicine. Radiology services include MRI, CT scans, X-ray, ultrasound with colour Doppler, mammography, Dexa scans and interventional radiology. Clinical laboratory services cover haematology, microbiology, immunology, pathology and biochemistry, while nuclear medicine services include PET-CT, SPECT and nuclear therapy. The company also provides teleradiology services through its registered office in Vijayawada, which operates 24×7. As of December 31, 2025, the company operated 15 diagnostic centres across six states and 13 cities in India. Its centres operate through public-private partnerships, private-private partnerships, strategic partnerships with government PSUs and standalone private centres. The company also has a processing unit-cum-laboratory in Vijayawada. Use of proceeds: The IPO consists of both a fresh issue of shares and an offer for sale (OFS).​ Proceeds from the OFS will go to the respective selling shareholders, whereas the net proceeds from the fresh issue will be utilised for the following purposes:​ Funding of capital expenditure for purchase of medical equipment towards existing and proposed diagnostic centres — Rs 45.15 crore General corporate purposes.